{"id":"ceftazidim","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Diarrhea","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"5%","severity":"common","organSystem":""}],"contraindications":["Blood coagulation disorder","Disease of liver","Factor II deficiency","Kidney disease","Pseudomembranous enterocolitis"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Death","drugRate":"2.5%","severity":"serious"},{"effect":"Death (CrCl 30-50 mL/min subgroup)","drugRate":"19.5%","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":["Fortum"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd","title":"AVYCAZ (CEFTAZIDIME, AVIBACTAM) POWDER, FOR SOLUTION [ALLERGAN, INC.]"},"ecosystem":[],"mechanism":{"target":"Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI"},"_scrapedAt":"2026-03-27T23:40:49.719Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Bacterial infection due to Klebsiella pneumoniae","diseaseId":"bacterial-infection-due-to-klebsiella-pneumoniae","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bacterial meningitis","diseaseId":"bacterial-meningitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bacterial pneumonia","diseaseId":"bacterial-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bacterial septicemia","diseaseId":"bacterial-septicemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bacterial urinary infection","diseaseId":"bacterial-urinary-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Citrobacter Pneumonia","diseaseId":"citrobacter-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Complicated Proteus UTI","diseaseId":"complicated-proteus-uti","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Complicated UTI with Pseudomonas Aeruginosa","diseaseId":"complicated-uti-with-pseudomonas-aeruginosa","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"E. Coli Cervicitis","diseaseId":"e.-coli-cervicitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"E. Coli Endometritis","diseaseId":"e.-coli-endometritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"E. Coli Gynecological Infections","diseaseId":"e.-coli-gynecological-infections","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"E. Coli Pelvic Cellulitis","diseaseId":"e.-coli-pelvic-cellulitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"E. Coli Pelvic Inflammatory Disease","diseaseId":"e.-coli-pelvic-inflammatory-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"E. Coli Peritonitis","diseaseId":"e.-coli-peritonitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Ecthyma gangrenosum","diseaseId":"ecthyma-gangrenosum","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Endometritis","diseaseId":"endometritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Enterobacter Osteomyelitis","diseaseId":"enterobacter-osteomyelitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Enterobacter Pneumonia","diseaseId":"enterobacter-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"EnterobacterJoint Infection","diseaseId":"enterobacterjoint-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Escherichia coli urinary tract infection","diseaseId":"escherichia-coli-urinary-tract-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Gonococcal meningitis","diseaseId":"gonococcal-meningitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"H. Influenzae Meningitis","diseaseId":"h.-influenzae-meningitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Haemophilus Septicemia","diseaseId":"haemophilus-septicemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Haemophilus influenzae pneumonia","diseaseId":"haemophilus-influenzae-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection due to Enterobacteriaceae","diseaseId":"infection-due-to-enterobacteriaceae","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection due to Escherichia coli","diseaseId":"infection-due-to-escherichia-coli","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection due to Staphylococcus aureus","diseaseId":"infection-due-to-staphylococcus-aureus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection of bone","diseaseId":"infection-of-bone","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection of skin AND/OR subcutaneous tissue","diseaseId":"infection-of-skin-and/or-subcutaneous-tissue","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infectious disease of abdomen","diseaseId":"infectious-disease-of-abdomen","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infectious disorder of joint","diseaseId":"infectious-disorder-of-joint","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Inflammatory Disease of Female Pelvic Organs","diseaseId":"inflammatory-disease-of-female-pelvic-organs","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Klebsiella Joint Infection","diseaseId":"klebsiella-joint-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Klebsiella Pneumoniae Osteomyelitis","diseaseId":"klebsiella-pneumoniae-osteomyelitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Klebsiella Pneumoniae Peritonitis","diseaseId":"klebsiella-pneumoniae-peritonitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Klebsiella cystitis","diseaseId":"klebsiella-cystitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Lower respiratory tract infection","diseaseId":"lower-respiratory-tract-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Meningococcal meningitis","diseaseId":"meningococcal-meningitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Neonatal meningitis","diseaseId":"neonatal-meningitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Osteomyelitis due to Staphylococcus aureus","diseaseId":"osteomyelitis-due-to-staphylococcus-aureus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Peritonitis","diseaseId":"peritonitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pneumonia due to Escherichia coli","diseaseId":"pneumonia-due-to-escherichia-coli","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pneumonia due to Pseudomonas","diseaseId":"pneumonia-due-to-pseudomonas","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pneumonia due to Streptococcus","diseaseId":"pneumonia-due-to-streptococcus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Proteus pneumonia","diseaseId":"proteus-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Proteus urinary tract infection","diseaseId":"proteus-urinary-tract-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pseudomonas Aeruginosa Joint Infection","diseaseId":"pseudomonas-aeruginosa-joint-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pseudomonas Aeruginosa Osteomyelitis","diseaseId":"pseudomonas-aeruginosa-osteomyelitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pseudomonas Aeruginosa Urinary Tract Infection","diseaseId":"pseudomonas-aeruginosa-urinary-tract-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Rhinoscleroma","diseaseId":"rhinoscleroma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Sepsis due to Pseudomonas","diseaseId":"sepsis-due-to-pseudomonas","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Sepsis due to Staphylococcus aureus","diseaseId":"sepsis-due-to-staphylococcus-aureus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Septicemia due to Escherichia coli","diseaseId":"septicemia-due-to-escherichia-coli","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Septicemia due to Serratia","diseaseId":"septicemia-due-to-serratia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Skin and Skin Structure Proteus Infection","diseaseId":"skin-and-skin-structure-proteus-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Skin and Skin Structure Pseudomonas Aeruginosa Infection","diseaseId":"skin-and-skin-structure-pseudomonas-aeruginosa-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Skin and Skin Structure Serratia Infection","diseaseId":"skin-and-skin-structure-serratia-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcal pneumonia","diseaseId":"staphylococcal-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcus Aureus Joint Infection","diseaseId":"staphylococcus-aureus-joint-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcus Peritonitis","diseaseId":"staphylococcus-peritonitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Streptococcal septicemia","diseaseId":"streptococcal-septicemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Streptococcus pyogenes infection","diseaseId":"streptococcus-pyogenes-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Urinary tract infection caused by Klebsiella","diseaseId":"urinary-tract-infection-caused-by-klebsiella","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07494981","phase":"","title":"Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations","status":"NOT_YET_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-03-25","conditions":"Ceftazidime-avibactam","enrollment":150},{"nctId":"NCT04948463","phase":"PHASE4","title":"Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2021-11-15","conditions":"Febrile Neutropenia","enrollment":55},{"nctId":"NCT06406114","phase":"PHASE2","title":"Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-05-05","conditions":"Drug Allergy, Cephalosporin Allergy, Drug Hypersensitivity","enrollment":300},{"nctId":"NCT07478484","phase":"PHASE4","title":"Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB","status":"RECRUITING","sponsor":"Jing Zhou","startDate":"2026-03-31","conditions":"Ceftazidime-avibactam, Aztreonam, Gram-negative Bacterial Infection","enrollment":144},{"nctId":"NCT04961580","phase":"","title":"PK/PD of Ceftazidime Avitbatan Sodium in Children With Severe Infection","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2022-10-01","conditions":"Sepsis, Antibiotic Reaction","enrollment":30},{"nctId":"NCT07431307","phase":"PHASE2","title":"Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex","status":"NOT_YET_RECRUITING","sponsor":"BioVersys AG","startDate":"2026-07","conditions":"Ventilator Associated Bacterial Pneumonia (VABP), Hospital Acquired Bacterial Pneumonia (HABP), Blood Stream Infection","enrollment":120},{"nctId":"NCT07327619","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-01-22","conditions":"Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia","enrollment":420},{"nctId":"NCT07311343","phase":"PHASE4","title":"Oral Hygiene and Prophylactic Antibiotics to Prevent Intracerebral Hemorrhage Associated Pneumonia","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2026-01-07","conditions":"Hemorrhage, Pneumonia","enrollment":440},{"nctId":"NCT07369518","phase":"","title":"Effect of Ceftazidime-Avibactam on Carbapenemase-Producing Klebsiella Pneumoniae","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-01","conditions":"ISOLATION OF KLEB. by Culture on macConkey Agar, Antibiotic Sensitivity Testing of Different Antibiotics According to Clsi 25, Effect of Ceftazidime-Avibactam on Carbapenemase-Producing Klebsiella Pneumoniae","enrollment":100},{"nctId":"NCT07318584","phase":"PHASE2","title":"Cefotetan Therapy for Escherichia Coli Infections","status":"NOT_YET_RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2026-03","conditions":"E Coli Infection, ESBL Producing E.Coli","enrollment":84},{"nctId":"NCT06717594","phase":"","title":"PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2023-12-01","conditions":"Gram Negative Infections, Antimicrobial Resistance (AMR)","enrollment":60},{"nctId":"NCT07085624","phase":"NA","title":"Early Optimization of Ceftazidime Regimen in Critical Care","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2026-01","conditions":"Infection in ICU, Sepsis, Septic Shock","enrollment":128},{"nctId":"NCT01543334","phase":"","title":"Antibiotic Concentrations Among Critically Ill Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2012-03","conditions":"Administration of Antibiotics in Intensive Care Units","enrollment":98},{"nctId":"NCT06864585","phase":"","title":"A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-03-15","conditions":"Infectious Diseases","enrollment":59},{"nctId":"NCT07204522","phase":"","title":"Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients.","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-09-22","conditions":"Febrile Neutropenia","enrollment":20},{"nctId":"NCT07063095","phase":"PHASE3","title":"A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections","status":"RECRUITING","sponsor":"Angela HUTTNER","startDate":"2025-08-25","conditions":"Gram Negative Infections, Sepsis and Septic Shock","enrollment":100},{"nctId":"NCT07160569","phase":"","title":"Microbiological and Clinical Characteristics of Severe Infections Caused by Carbapenem-Resistant Enterobacterales","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-09-01","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":100},{"nctId":"NCT05487586","phase":"","title":"Real-World Study of Ceftazidime Avibactam in China","status":"TERMINATED","sponsor":"Pfizer","startDate":"2022-10-20","conditions":"Hospital Acquired Pneumonia, Ventilator Acquired Pneumonia, Complicated Intra Abdominal Infections","enrollment":220},{"nctId":"NCT05733104","phase":"","title":"A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-02-19","conditions":"Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection, Hospital-acquired Pneumonia","enrollment":600},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT07016165","phase":"PHASE4","title":"Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies","status":"RECRUITING","sponsor":"Gadjah Mada University","startDate":"2025-06-01","conditions":"Neutropenic Fever, Acute Lymphoblastic Leukemia, Acute Myeloblastic Leukemia","enrollment":120},{"nctId":"NCT05413343","phase":"","title":"Clinical Study on Monitoring the Plasma Concentration of Ceftazidime-Avibactam in Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2021-06-01","conditions":"Severe Sepsis","enrollment":30},{"nctId":"NCT07089186","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-04-12","conditions":"Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP), Complicated Intra-abdominal Infection (cIAI)","enrollment":80},{"nctId":"NCT06112938","phase":"","title":"Alternative Treatment Strategies for Stenotrophomonas Maltophilia Pneumonia","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2022-07-21","conditions":"Stenotrophomonas Maltophilia Infection","enrollment":110},{"nctId":"NCT06368804","phase":"PHASE2","title":"Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With PA in Adults With Bronchiectasis","status":"RECRUITING","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2024-09-15","conditions":"Bronchiectasis","enrollment":196},{"nctId":"NCT07026253","phase":"","title":"Comparative Analysis of Delirium in Older Adults Treated With Ceftazidime, Cefepime, or Ceftriaxone","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2024-10-01","conditions":"Delirium","enrollment":120},{"nctId":"NCT07004049","phase":"PHASE4","title":"Optimising TREATment for Severe Gram-Negative Bacterial Infections","status":"RECRUITING","sponsor":"National University of Singapore","startDate":"2025-04-21","conditions":"Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia","enrollment":600},{"nctId":"NCT06992102","phase":"","title":"Clinical Study on the Treatment of Lower Respiratory Tract Infection With Pseudomonas Aeruginosa by Ceftazidime and Avibatam","status":"COMPLETED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-01-01","conditions":"MDRPA","enrollment":500},{"nctId":"NCT03790631","phase":"","title":"The OPTIMAL TDM Study: Determining Optimal Beta-lactam Plasma Concentrations Through Therapeutic Drug Monitoring","status":"COMPLETED","sponsor":"University of Geneva, Switzerland","startDate":"2019-01-14","conditions":"Beta-lactam Antibiotics, Therapeutic Drug Monitoring, Toxicity","enrollment":771},{"nctId":"NCT06051513","phase":"NA","title":"Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection","status":"RECRUITING","sponsor":"Southeast University, China","startDate":"2023-11-27","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":404},{"nctId":"NCT06967376","phase":"EARLY_PHASE1","title":"The Role of Adjuvant Corneal Crosslinking in the Management of Infective Keratitis","status":"COMPLETED","sponsor":"Research Institute of Ophthalmology, Egypt","startDate":"2018-05-21","conditions":"Infective Keratitis","enrollment":40},{"nctId":"NCT06939829","phase":"PHASE4","title":"A Multicenter Clinical Study on the Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe Infections","status":"NOT_YET_RECRUITING","sponsor":"Southeast University, China","startDate":"2025-05-01","conditions":"Patients With Critically Ill Infections","enrollment":1200},{"nctId":"NCT06811727","phase":"PHASE4","title":"CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients","status":"NOT_YET_RECRUITING","sponsor":"Ivan Šitum, MD","startDate":"2025-05-01","conditions":"Severe Infection","enrollment":140},{"nctId":"NCT02526004","phase":"NA","title":"Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified","status":"COMPLETED","sponsor":"University College Cork","startDate":"2013-10-01","conditions":"Cystic Fibrosis","enrollment":223},{"nctId":"NCT04077996","phase":"NA","title":"Treatment of Peritonitis in Automated Peritoneal Dialysis","status":"COMPLETED","sponsor":"Universidad de Colima","startDate":"2019-07-01","conditions":"Secondary Peritonitis","enrollment":64},{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":"Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children","enrollment":5000},{"nctId":"NCT06818565","phase":"NA","title":"Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-02-10","conditions":"Acute-On-Chronic Liver Failure","enrollment":150},{"nctId":"NCT06044272","phase":"","title":"Antimicrobial Resistance in Hospitals From Meta, Colombia","status":"COMPLETED","sponsor":"Hospital Departamental de Villavicencio","startDate":"2023-09-01","conditions":"Increased Drug Resistance","enrollment":10000},{"nctId":"NCT06729619","phase":"","title":"Concentration Monitoring of Anti-infective Drugs in Human Cerebrospinal Fluid and Its Clinical Application","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xueyan Cui","startDate":"2024-06-03","conditions":"Intracranial Infection, Central Infection","enrollment":200},{"nctId":"NCT06419296","phase":"","title":"Mortality of MBL-producing Enterobacteriaceae Bacteremias with the Combined Use of Ceftazidime-avibactam and Aztreonam Vs. Other Active Antibiotics. a Multicenter Target Trial Emulation.","status":"COMPLETED","sponsor":"Hospital Italiano de Buenos Aires","startDate":"2024-06-01","conditions":"Bacteremia","enrollment":265},{"nctId":"NCT04882085","phase":"PHASE4","title":"Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-26","conditions":"Urinary Tract Infection, Acute Pyelonephritis, Hospital Acquired Pneumonia","enrollment":60},{"nctId":"NCT06651047","phase":"","title":"PK/PD Analysis of Ceftazidime/Avibactam or Cefiderocol With or Without Fosfomycin for the Treatment of Difficult To-treat Gram-negative Infections","status":"RECRUITING","sponsor":"University of Bologna","startDate":"2024-07-09","conditions":"Gram Negative Infection, Antimicrobial Resistance (AMR)","enrollment":120},{"nctId":"NCT06633718","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-10-31","conditions":"Intra-abdominal Infections","enrollment":786},{"nctId":"NCT04774094","phase":"PHASE4","title":"Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-05-21","conditions":"Hospital-Acquired Pneumonia","enrollment":235},{"nctId":"NCT04785924","phase":"PHASE4","title":"Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2021-06-07","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection, KPC, Gram-Negative Bacterial Infections","enrollment":""},{"nctId":"NCT04628572","phase":"","title":"Retrospective Analysis of Real World Use of Ceftazidime-avibactam in the Management of Gram Negative Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-01-29","conditions":"Gram Negative Infections","enrollment":189},{"nctId":"NCT06539663","phase":"PHASE2, PHASE3","title":"The Role of OmniLenz® in the Treatment of Small Corneal Perforations Secondary to Exposure Keratitis in ICU Patients","status":"COMPLETED","sponsor":"Farwaniya Hospital","startDate":"2022-04-10","conditions":"Corneal Perforation, Exposure Keratitis, Infectious Keratitis","enrollment":5},{"nctId":"NCT06528028","phase":"PHASE4","title":"Relationship Between Different Administration Regimens of Ceftazidime/Avibactam and Clinical Outcomes","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-07-01","conditions":"Anti-Infective Agent","enrollment":140},{"nctId":"NCT05786495","phase":"NA","title":"Short Antibiotic Treatment in High Risk Febrile Neutropenia","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-10-01","conditions":"Febrile Neutropenia","enrollment":80},{"nctId":"NCT05566665","phase":"","title":"Nosocomial Infections in ECMO Patients","status":"RECRUITING","sponsor":"Policlinico Hospital","startDate":"2023-01-01","conditions":"Acute Respiratory Distress Syndrome, Nosocomial Infection, Extracorporeal Membrane Oxygenation Complication","enrollment":200},{"nctId":"NCT03923426","phase":"","title":"Real-World Observational Study Of Zavicefta to Characterize Use Patterns","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-11-27","conditions":"Infection","enrollment":572},{"nctId":"NCT05048693","phase":"","title":"Use of New Antibiotics in Sweden","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2021-11-01","conditions":"Multi-antibiotic Resistance","enrollment":41},{"nctId":"NCT05258851","phase":"PHASE3","title":"Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections","status":"TERMINATED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2022-06-01","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":29},{"nctId":"NCT06422533","phase":"NA","title":"Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients","status":"RECRUITING","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2023-11-07","conditions":"Hematologic Neoplasms, Neutropenia","enrollment":226},{"nctId":"NCT04192994","phase":"NA","title":"Evaluation do Early Pars Plana Vitrectomy in Acute Endophthalmitis","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2019-01-01","conditions":"Endophthalmitis","enrollment":25},{"nctId":"NCT04319328","phase":"","title":"Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?","status":"COMPLETED","sponsor":"University of Manitoba","startDate":"2019-10-18","conditions":"Hemodialysis Complication, Infectious Disease, End Stage Renal Disease","enrollment":40},{"nctId":"NCT04126031","phase":"PHASE2","title":"Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-01-14","conditions":"Gram-negative Bacterial Infection","enrollment":48},{"nctId":"NCT04927312","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-10-01","conditions":"Complicated Intra-abdominal Infection","enrollment":60},{"nctId":"NCT05926063","phase":"PHASE4","title":"Stopping Antibiotics After 3 Days for the Treatment of High-risk FEbrile Neutropenia","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2024-02-26","conditions":"Neutropenia, Febrile","enrollment":410},{"nctId":"NCT05979545","phase":"PHASE4","title":"EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics","status":"RECRUITING","sponsor":"National University of Singapore","startDate":"2023-12-12","conditions":"Blood Stream Infections, Ventilator Associated Pneumonia, Healthcare Associated Infection","enrollment":1900},{"nctId":"NCT01785641","phase":"NA","title":"Single Versus Combined Antibiotic Therapy for Bacterial Peritonitis in CAPD Patients","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2012-12","conditions":"Peritonitis","enrollment":300},{"nctId":"NCT05105035","phase":"PHASE2","title":"Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Treatment of Melioidosis in Hospitalized Patients","status":"COMPLETED","sponsor":"Arrevus Inc.","startDate":"2022-06-14","conditions":"Melioidosis","enrollment":125},{"nctId":"NCT03897582","phase":"","title":"Beta-Lactams Dosing In Pneumonia in ICU in Patients Treated by Continuous Renal Replacement Therapy: the BLIPIC Study","status":"RECRUITING","sponsor":"Centre Hospitalier de Valenciennes","startDate":"2019-02-22","conditions":"Beta-lactam, Continuous Renal Replacement Therapy, Pneumonia","enrollment":65},{"nctId":"NCT05971537","phase":"PHASE4","title":"Clinical Trial on Antibiotic-Lock in Tenckhoff Catheter for Relasping and Repeat Peritonitis","status":"RECRUITING","sponsor":"Alice Ho Miu Ling Nethersole Hospital","startDate":"2023-06-15","conditions":"Peritoneal Dialysis-associated Peritonitis","enrollment":46},{"nctId":"NCT05655689","phase":"","title":"The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2021-12-31","conditions":"Bacterial Keratitis, Fungal Keratitis, Mixed Bacterial and Fungal Keratitis","enrollment":123},{"nctId":"NCT06210542","phase":"","title":"Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK Model","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Provincial People's Hospital","startDate":"2024-01","conditions":"ECMO, Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":50},{"nctId":"NCT04033029","phase":"","title":"Antibiotic Plasma Concentrations During Continuous Renal Replacement Therapy With a High Adsorption Membrane (oXiris®)","status":"COMPLETED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2021-01-01","conditions":"Hemodiafiltration, Sepsis, Acute Kidney Injury","enrollment":20},{"nctId":"NCT05862402","phase":"PHASE4","title":"Dose Optimization by Pharmacokinetic/Pharmacodynamic of Antibiotics to Improve Clinical Outcome of Carbapenem Resistant Klebsiella Pneumoniae Bloodstream Infections in Critically Ill Patients at Phramongkutklao Hospital","status":"UNKNOWN","sponsor":"Phramongkutklao College of Medicine and Hospital","startDate":"2023-05-07","conditions":"Carbapenem Resistant Klebsiella Pneumoniae","enrollment":76},{"nctId":"NCT03439124","phase":"PHASE3","title":"Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia","status":"COMPLETED","sponsor":"Basilea Pharmaceutica","startDate":"2017-11-27","conditions":"Community-acquired Pneumonia (CAP), Hospital-acquired Pneumonia (HAP)","enrollment":138},{"nctId":"NCT04035369","phase":"NA","title":"Endophthalmitis Post Intravitreal Injections","status":"UNKNOWN","sponsor":"Unity Health Toronto","startDate":"2020-03-01","conditions":"Endophthalmitis","enrollment":310},{"nctId":"NCT05850871","phase":"NA","title":"Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2023-01-06","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":427},{"nctId":"NCT03147807","phase":"NA","title":"BetaLACTA® Test for Early De-escalation of Empirical Carbapenems in Pulmonary, Urinary and Bloodstream Infections in ICU","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-10-20","conditions":"Pneumonia, Urinary Tract Infections, Bloodstream Infection","enrollment":75},{"nctId":"NCT03909698","phase":"","title":"Antibiotic Dosing in Patients on Intermittent Hemodialysis","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2016-09-15","conditions":"Kidney Failure, Chronic, Antibiotics, Hemodialysis","enrollment":150},{"nctId":"NCT03881800","phase":"","title":"Ceftazidime in Burn Children","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-02-19","conditions":"Burned Children, Ceftazidime Treatment","enrollment":3},{"nctId":"NCT04040621","phase":"PHASE1","title":"Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-06-15","conditions":"Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia","enrollment":4},{"nctId":"NCT03978091","phase":"PHASE1, PHASE2","title":"A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-07-09","conditions":"Bacterial Infection","enrollment":48},{"nctId":"NCT02840136","phase":"NA","title":"LC-MS/MS Based Method Development for the Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients","status":"TERMINATED","sponsor":"University Ghent","startDate":"2016-02","conditions":"Cystic Fibrosis","enrollment":40},{"nctId":"NCT02287493","phase":"","title":"Pharmacokinetics of Selected Antiinfectives During Sustained Low-efficiency Dialysis (SLED)","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2013-07","conditions":"Replacement Therapy, Renal","enrollment":35},{"nctId":"NCT03790176","phase":"PHASE1","title":"ZAVI APD ELF Protocol v2.2","status":"UNKNOWN","sponsor":"Markus Zeitlinger","startDate":"2018-10-01","conditions":"Peritonitis, Pneumonia","enrollment":20},{"nctId":"NCT04167228","phase":"","title":"Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria","status":"COMPLETED","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2019-10-01","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":348},{"nctId":"NCT04879030","phase":"PHASE2, PHASE3","title":"Combination Antibiotic Therapy Compared to Monotherapy in the Treatment of Acute COPD","status":"COMPLETED","sponsor":"Haiphong University of Medicine and Pharmacy","startDate":"2020-01-01","conditions":"COPD Exacerbation Acute","enrollment":170},{"nctId":"NCT04771884","phase":"","title":"Population Pharmacokinetics of Commonly Used Antimicrobial Agents in Children of Bacterial Meningitis With Augmented Renal Clearance","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2020-10-01","conditions":"Bacterial Meningitis, Augmented Renal Clearance","enrollment":300},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT04358991","phase":"","title":"Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving CVVHDF","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2017-01-01","conditions":"Bacterial Infections","enrollment":20},{"nctId":"NCT02795949","phase":"PHASE3","title":"Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2016-10","conditions":"Enterobacteriaceae Infections","enrollment":344},{"nctId":"NCT03776409","phase":"","title":"Safety and Efficacy of Vancomycin Plus Beta-lactams","status":"COMPLETED","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2018-12-12","conditions":"Critical Illness","enrollment":700},{"nctId":"NCT04402359","phase":"","title":"Usage of Meropenem/Gentamicin Versus Ceftazidime/Avibactam in ARDS","status":"COMPLETED","sponsor":"King Abdul Aziz Specialist Hospital","startDate":"2018-07-05","conditions":"Ventilator Associated Pneumonia","enrollment":200},{"nctId":"NCT03941951","phase":"NA","title":"Study to Optimize the Use of New Antibiotics","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2019-07-09","conditions":"Bacterial Infections, Fungal Infection","enrollment":900},{"nctId":"NCT04367974","phase":"","title":"Clinical Pharmacokinetic Study of Ceftazidime and Cefazolin","status":"UNKNOWN","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2020-06-01","conditions":"CAPD-related Peritonitis","enrollment":20},{"nctId":"NCT02787057","phase":"NA","title":"Vancomycin Plus Moxifloxacin Versus Vancomycin Plus Ceftazidime for the Treatment of Peritoneal Dialysis (PD)-Related Peritonitis","status":"COMPLETED","sponsor":"Peking University First Hospital","startDate":"2012-11","conditions":"Peritoneal Dialysis Associated Peritonitis","enrollment":80},{"nctId":"NCT04187755","phase":"PHASE4","title":"Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2019-03-01","conditions":"Neutropenia, Febrile, Leukemia, Pediatric Cancer","enrollment":72},{"nctId":"NCT02593201","phase":"PHASE4","title":"The Efficacy of Prolonged Antibiotic Therapy for the Prevention of Relapsing Peritonitis in Peritoneal Dialysis Patients With High Dialysis Effluent Bacterial DNA Fragment Levels","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2016-02-26","conditions":"Peritoneal Dialysis","enrollment":358},{"nctId":"NCT02894684","phase":"PHASE4","title":"Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis","status":"COMPLETED","sponsor":"Liverpool Heart and Chest Hospital NHS Foundation Trust","startDate":"2017-01","conditions":"Cystic Fibrosis, Infection, Pseudomonas","enrollment":16},{"nctId":"NCT01601093","phase":"PHASE2","title":"Study on Ceftazidime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection","status":"SUSPENDED","sponsor":"Xiangbei Welman Pharmaceutical Co., Ltd","startDate":"2011-11","conditions":"Respiratory Tract Infections, Urinary Tract Infections","enrollment":288},{"nctId":"NCT03960905","phase":"","title":"A Study the Population Pharmacokinetics of Children of Infectious Disease in Central Nervous System","status":"UNKNOWN","sponsor":"Wei Zhao","startDate":"2019-01-01","conditions":"Central Nervous System Infection","enrollment":800},{"nctId":"NCT03243864","phase":"","title":"Study of Ceftazidime-Avibactam Blood Concentrations in Intensive Care Unit Patients With Renal Failure Requiring Continuous Dialysis","status":"UNKNOWN","sponsor":"Temple University","startDate":"2017-03-13","conditions":"Renal Failure, Bacterial Infections, Critical Illness","enrollment":10},{"nctId":"NCT02822950","phase":"PHASE1","title":"A Study of Avycaz (Ceftazidime/Avibactam) Pharmacokinetics/Pharmacodynamics (PK/PD) in Critically Ill Patients","status":"COMPLETED","sponsor":"Michigan State University","startDate":"2017-01","conditions":"Pharmacokinetics of Avycaz in ICU Patients","enrollment":10},{"nctId":"NCT03754387","phase":"NA","title":"Antibiotic Therapy vs Laparscopic Appendectomy in Pediatric Chronic Appendicitis","status":"UNKNOWN","sponsor":"Zunyi Medical College","startDate":"2019-01-01","conditions":"Chronic Appendicitis","enrollment":200},{"nctId":"NCT02504827","phase":"PHASE4","title":"Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2015-09","conditions":"Cystic Fibrosis","enrollment":12},{"nctId":"NCT03404739","phase":"PHASE2, PHASE3","title":"Single- Versus Multiple-dose Antimicrobial Prophylaxis for The Prevention of Infectious Complications Associated With Peroral Endoscopic Myotomy(POEM) for Achalasia","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2017-10-01","conditions":"Esophageal Achalasia","enrollment":666}],"_emaApprovals":[],"_faersSignals":[{"count":18,"reaction":"SEPSIS"},{"count":16,"reaction":"PNEUMONIA"},{"count":14,"reaction":"DRUG INEFFECTIVE"},{"count":11,"reaction":"PANCYTOPENIA"},{"count":10,"reaction":"BRONCHOPULMONARY ASPERGILLOSIS"},{"count":10,"reaction":"NEUTROPENIA"},{"count":10,"reaction":"THROMBOCYTOPENIA"},{"count":9,"reaction":"PYREXIA"},{"count":9,"reaction":"RESPIRATORY FAILURE"},{"count":8,"reaction":"CYTOMEGALOVIRUS INFECTION"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":127,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Ceftazidim","genericName":"Ceftazidim","companyName":"Tel-Aviv Sourasky Medical Center","companyId":"tel-aviv-sourasky-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}